Insight Molecular Diagnostics
IMDX
26 hedge funds and large institutions have $21.8M invested in Insight Molecular Diagnostics in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.04% less ownership
Funds ownership: 1.11% → 1.07% (-0.04%)
3% less capital invested
Capital invested by funds: $22.4M → $21.8M (-$594K)
21% less funds holding
Funds holding: 33 → 26 (-7)
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DWM
Destination Wealth Management
Walnut Creek,
California
|
+$76.5K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$62.3K |
| 3 |
Morgan Stanley
New York
|
+$47.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$238K |
| 2 |
Goldman Sachs
New York
|
-$47K |
| 3 |
ECM
Element Capital Management
New York
|
-$33.1K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$32K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$27K |
IMDX Hedge Fund Activity: Q3 2018 in Review
26 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2018, worth a combined $21.8M — down 2.7% from $22.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IMDX and 2 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Destination Wealth Management, opening a new position worth an estimated $76.5K. The largest seller was Millennium Management, cutting an estimated $238K.
- 26 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2018, down from 33 in Q2 2018.
- Funds reported $21.8M of Insight Molecular Diagnostics stock for Q3 2018, down 2.7% quarter-over-quarter.
- 2 funds opened new Insight Molecular Diagnostics positions in Q3 2018 and 9 closed out, a net change of -7 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2018 was Destination Wealth Management, an estimated $76.5K added.
- The largest Insight Molecular Diagnostics seller in Q3 2018 was Millennium Management, an estimated $238K sold.
Based on aggregated 13F filings for Q3 2018.